Disrupting USP39 Function Impairs Multiple Myeloma Cell Survival and Migration
Author Information
Author(s): Sirera Jessy, Sarlak Saharnaz, Teisseire Manon, Carminati Alexandrine, Nicolini Victoria J., Savy Coline, Brest Patrick, Juel Thierry, Bontoux Christophe, Deckert Marcel, Ohanna Mickael, Giuliano Sandy, Dufies Maeva, Pages Gilles, Luciano Frederic
Primary Institution: Institute for Research On Cancer and Aging of Nice (IRCAN), University Côte d’Azur, Nice, France
Hypothesis
Is USP39 a critical survival factor for multiple myeloma cells?
Conclusion
Targeting USP39 could serve as a potential therapeutic strategy in multiple myeloma by impairing cell survival and migration.
Supporting Evidence
- USP39 mRNA levels are associated with shorter survival in multiple myeloma patients.
- USP39 protein is significantly higher in multiple myeloma patient plasmocytes compared to healthy individuals.
- Knockdown of USP39 inhibits clonogenic capacity and induces apoptosis in multiple myeloma cells.
- USP39 stabilizes ZEB1, enhancing the proliferation and migration of multiple myeloma cells.
Takeaway
Researchers found that a protein called USP39 helps multiple myeloma cells survive and move around, and blocking it could help treat the disease.
Methodology
The study used a loss-of-function screen to identify USP39's role, along with gene expression analysis, immunohistochemistry, and in vitro assays.
Potential Biases
Potential bias in sample selection and analysis methods.
Limitations
The study primarily focused on in vitro models and may not fully represent in vivo conditions.
Participant Demographics
Patients diagnosed with multiple myeloma, primarily aged 60-70.
Statistical Information
P-Value
0.038
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website